Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain

European Journal of Pharmacology

Volumn 660, Issue 2-3, 2011, Pages 318-325

  Ikeda, Rie ^a   Igari, Yoshiko ^a   Fuchigami, Yuki ^a   Wada, Mitsuhiro ^a   Kuroda, Naotaka ^a   Nakashima, Kenichiro ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

3,4 Methylenedioxymethamphetamine; Caffeine; Dopamine; Interaction; Ketamine; Methamphetamine; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CAFFEINE; DOPAMINE; KETAMINE; METHAMPHETAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EXPOSURE; DRUG POTENTIATION; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; CAFFEINE; DOPAMINE; DRUG INTERACTIONS; EXTRACELLULAR SPACE; KETAMINE; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, WISTAR; SEROTONIN; TABLETS;

EID: 79956141103     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.050     Document Type: Article

References (53)

1. Adachi, Y.U., Watanabe, K., Satoh, T., Vizi, E.S., 2001. Halothane potentiates the effect of methamphetamine and nomifensine on extracellular dopamine levels in rat striatum: a microdialysis study. Br. J. Anaesth. 86, 837-845.
2. Ahmad, K., 2002. Increased use of amphetamine-type stimulants threatens east Asian countries. Lancet 359, 1927.
3. Banken, J.A., 2004. Drug abuse trends among youth in the United States. Ann. N. Y. Acad. Sci. 1025, 465-471.
4. Baumann, M.H., Wang, X., Rothman, R.B., 2007. 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology 189, 407-424. (Pubitemid 44791212)
5. Benamar, K., Geller, E.B., Adler, M.W., 2008. A new brain area affected by 3,4-methylenedioxymethamphetamine: a microdialysis-biotelemetry study. Eur. J. Pharmacol. 596, 84-88.
6. Camarasa, J., Pubill, D., Escubedo, E., 2006. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. Brain Res. 1111, 72-82. (Pubitemid 44331182)
7. Capela, J.P., Carmo, H., Remião, F., Bastos, M.L., Meisel, A., Carvalho, F., 2009. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 39, 210-217.
8. Chu, T., Kumagai, Y., DiStefano, E.W., Cho, A.K., 1996. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem. Pharmacol. 51, 789-796.
9. Clemens, K.J., van Nieuwenhuyzen, P.S., Li, K.M., Cornish, J.L., Hunt, G.E., McGregor, I.S., 2004. MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology 173, 318-325. (Pubitemid 38703805)
10. Clemens, K.J., Cornish, J.L., Li, K.M., Hunt, G.E., McGregor, I.S., 2005. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 49, 195-207. (Pubitemid 40933758)
11. Clemens, K.J., Cornish, J.L., Hunt, G.E., McGregor, I.S., 2007. Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. Drug Alcohol Depend. 86, 183-190. (Pubitemid 44821601)
12. Colad, M.I., O'Shea, E., Green, A.R., 2004. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology 173, 249-263. (Pubitemid 38703798)
13. Cole, J.C., Sumnall, H.R., 2003. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci. Behav. Rev. 27, 199-217.
14. Cole, J.C., Bailey, M., Sumnall, H.R., Wagstaff, G.F., King, L.A., 2002. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97, 1531-1536. (Pubitemid 36009109)
15. de la Torre, R., Farré, M., Ortuño, J., Mas, M., Brenneisen, R., Roset, P.N., Segura, J., Cami, J., 2000. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol. 49, 104-109.
16. Duterte, M., Jacinto, C., Sales, P., Murphy, S., 2009. What's in a label? Ecstasy sellers' perceptions of pill brands. J. Psychoactive Drugs 41, 27-37.
17. Eede, H.V., Monteiji, L.J., Touw, D.J., Norris, E.M., in press. Rhabdomyolysis in MDMA intoxication: a rapid and underestimated killer. "Clean" ecstasy: a safe party drug? J. Emerg. Med.
18. Erives, G.V., Lau, S.S., Monks, T.J., 2008. Accumulation of neurotoxic thioether metabolites of 3,4-methylenedioxymethamphetamine in rat brain. J. Pharmacol. Exp. Ther. 324, 284-292.
19. Escobedo, I., O'Shea, E., Orio, L., Sanchez, V., Segura, M., de la Torre, R., Farre, M., Green, A.R., Colado, M.I., 2005. A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br. J. Pharmacol. 144, 231-241.
20. Goni-Allo, B., Ó Mathúna, B., Segura, M., Puerta, E., Lasheras, B., de la Torre, R., Aguirre, N., 2008. The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology 189, 407-424.
21. Gudelsky, G.A., Yamamoto, B.K., 2008. Actions of 3,4- methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol. Biochem. Behav. 90, 198-207.
22. Kalant, H., 2001. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165, 917-928.
23. Ke, J.J., Ho, M.C., Cherng, C.G., Tsai, C.W., Yu, L., 2008. Ketamine pretreatment exacerbated 3,4-methylenedioxymethamphetamine-induced central dopamine toxicity. Chin. J. Physiol. 51, 65-70.
24. Koch, S., Escobedo, I., Orio, L., Sanchez, V., Navarro, M., Green, A.R., Colado, M.I., 1997. MDMA induced dopamine release in vivo: role of endogenous serotonin. J. Neural Transm. 104, 135-146. (Pubitemid 27196470)
25. Kolbrich, E.A., Goodwin, R.S., Gorelick, D.A., Hayes, R.J., Stein, E.A., Huestis, M.A., 2008. Plasma pharmacokinetics of 3,4- methylenedioxymethamphetamine after controlled oral administration to young adults. Ther. Drug Monit. 30, 320-332.
26. Kuwayama, K., Inoue, H., Kanamori, T., Tsujikawa, K., Miyaguchi, H., Iwata, Y., Miyauchi, S., Kamo, N., Kishi, T., 2007. Interactions between 3,4-methylenedioxymethamphetamine, methamphetamine, ketamine, and caffeine in human intestinal Caco-2 cells and in oral administration to rats. Forensic Sci. Int. 170, 1531-1536.
27. Loch, J.M., Potter, J., Bachmann, K.A., 1995. The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo. Pharmacology 50, 146-153.
28. Makino, Y., Tanaka, S., Kurobane, S., Nakauchi, M., Terasaki, T., Ohta, S., 2003. Profiling of illegal amphetamine-type stimulant tablets in Japan. J. Health Sci. 49, 129-137. (Pubitemid 41301480)
29. McCann, U.D., Ricaurte, G.A., 2001. Caveat emptor: editors beware. Neuropsychopharmacology 24, 333-334.
30. McNakamura, R., Kerans, A., O'Neill, B., Harkin, A., 2006. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love"). Neuropharmacology 50, 69-80.
31. McNakamura, R., Maginn, M., Harkin, A., 2007. Caffeine induces a profound and persistent tachycardia in response to MDMA ("Ecstasy") administration. Nur. J. Pharmacol. 555, 194-198.
32. Mechan, A.O., Esteban, B., O'Shea, E., Elliot, J.M., Colado, M.I., Green, A.R., 2002. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br. J. Pharmacol. 135, 170-180.
33. Meneguz, A., Fortuna, S., Lorenzini, P., Volpe, M.T., 1999. Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo. Exp. Toxicol. Pathol. 51, 392-396.
34. Mueller, M., Peters, F.T., Maurer, H.H., McCann, U.D., Ricaurte, G.A., 2008. Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. J. Pharmacol. Exp. Ther. 327, 38-44.
35. Parrott, A.C., 2001. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum. Psychopharmacol. 16, 557-577.
36. Paxinos, G., Watson, C., 2005. The Rat Brain in Stereotaxic Coordinates, fifth ed. Elsevier Academic Press, California, USA.
37. Pifl, C., Nagy, G., Berényi, S., Kattinger, A., Reither, H., Antus, S., 2005. Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters. J. Pharmacol. Exp. Ther. 314, 346-354.
38. Quinton, M.S., Yamamoto, B.K., 2006. Causes and consequences of methamphetamine and MDMA toxicity. AAPS 8, E337-E347. (Pubitemid 43790783)
39. Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I., Partilla, J.S., 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32-41.
40. 2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum. Brain Res. 1283, 115-126.
41. Sun, Y., Nakashima, M.N., Takahashi, M., Kuroda, N., Nakashima, K., 2002. Determination of bisphenol A in rat brain by microdialysis and column switching high-performance liquid chromatography with fluorescence detection. Biomed. Chromatogr. 16, 319-326.
42. Sweeney, B.P., Bromilow, J., 2006. Liver enzyme induction and inhibition: implications for anaesthesia. Anaesthesia 61, 159-177. (Pubitemid 43337407)
43. Tanner-Smith, E.E., 2006. Pharmacological content of tablets sold as "ecstasy": results from an online testing service. Drug Alcohol Depend. 83, 247-254.
44. Teng, S.F., Wu, S.C., Liu, C., Li, J.H., Chien, S.C., 2006. Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Forensic Sci. Int. 161, 202-208. (Pubitemid 44142909)
45. Tomita, M., Nakashima, M.N., Wada, M., Nakashima, K., 2007. Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. Biomed. Chromatogr. 21, 1016-1022.
46. Tsuruta, Y., Nishida, T., Xia, B., Maki, K., Uchikanbori, M., 2000. An experimental study of dietary therapy on osteoporotic mandibular alveolus in young rats-on bone matrix formation. J. Kyushu Dent. Soc. 54, 412-425.
47. Verma, A., Moghaddam, B., 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16, 373-379. (Pubitemid 26010723)
48. Verrico, C.D., Miller, G.M., Madras, B.K., 2007. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189, 489-503. (Pubitemid 44791219)
49. Vogels, N., Brunt, T.M., Rigter, S., van Dijk, P., Vervaeke, H., Niesink, R.J., 2009. Content of ecstasy in the Netherlands: 1993-2008. Addiction 104, 2057-2066.
50. Wada, M., Yokota, C., Ogata, Y., Kuroda, N., Yamada, H., Nakashima, K., 2008. Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminary study of the pharmacokinetic interaction between morphine and diclofenac. Anal. Bioanal. Chem. 391, 1057-1062.
51. Wu, Z.H., Holzer III, C.E., Breitkopf, C.R., Grady, J.J., Berenson, A.B., 2006. Patterns and perceptions of ecstasy use among young, low-income women. Addict. Behav. 31, 676-685.
52. Yamamoto, B.K., Nash, J.F., Gudelsky, G.A., 1995. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and γ-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 273, 1063-1070.
53. Yamaoka, K., Nakagawa, T., Uno, T., 1978. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6, 547-558.